Nephrolithiasis With Dorzolamide

Carlsen, Jeff; Durcan, Jane; Zabriskie, Norman A.; Swartz, Mano; Crandall, Alan S.

doi:10.1001/archopht.117.8.1087

Cited by 41 publications

(13 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IOP lowering data in normotensive rabbits with several of the most active in vitro CA inhibitors reported here, such as compounds 10,11,15,18,30,31,39 and 42 (Table III), indicate that the derivatives incorporating 4-(2-amino-pyrimidin-4-yl-amino)benzenesulfonamide scaffolds may act as efficient antiglaucoma agents in experimental animals. Thus, except for the derivatives incorporating arylsulfonylureido moieties (41 -45) which do not possess IOP lowering properties (although they were among the most potent in vitro inhibitors) -a phenomenon that will be explained below-both sulfonamides of type 1 -35 as well as carboxamides of type 36 -40 were effective IOP lowering agents after topical administration into the eye, as 2% suspensions/solutions.…”

Section: Discussionmentioning

confidence: 74%

Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold

Casini

Mincione²,

Vullo

et al. 2002

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

Reaction of 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide with alkyl/aryl-sulfonyl halides, acyl halides or arysulfonyl isocyanates afforded a series of derivatives which were tested for inhibition of three carbonic anhydrase (CA) isozymes. These compounds were designed in such a way as to (i) strongly inhibit several CA isozymes involved in aqueous humor secretion within the eye (such as CA II and CA IV), and (ii) to possess a pharmacological profile that allows easy penetration through the cornea, when administered as eye drops in solution or suspension, constituting thus a valuable therapeutic approach for glaucoma. Several of the obtained inhibitors showed low nanomolar affinities for the two isozymes involved in aqueous humor secretion, CA II and CA IV. Furthermore, in normotensive and hypertensive rabbits, some of them showed an effective and prolonged intraocular pressure (IOP) lowering when administered topically, as 2% suspensions/solutions.

show abstract

Section: Discussionmentioning

confidence: 74%

Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold

Casini

Mincione²,

Vullo

et al. 2002

Journal of Enzyme Inhibition and Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…Acetazolamide and dorzolamide are carbonic anhydrase inhibitors that alkalinize urine through the reduction of bicarbonate reabsorption [64]. They are commonly used as an adjunct to other drugs in the treatment of refractory [80], post-hemorrhagic hydrocephalus in preterm infants [64], or glaucoma [81]. These drugs are known for their lithogenic effects in adults [81,82]; however, there is a lack of data about their effect in the pediatric population.…”

Section: Other Diureticsmentioning

confidence: 99%

Drug-Induced Urolithiasis in Pediatric Patients

et al. 2019

View full text Add to dashboard Cite

Drug-induced nephrolithiasis is a rare condition in children. The involved drugs may be divided into two different categories according to the mechanism involved in calculi formation. The first one includes poorly soluble drugs that favor the crystallization and calculi formation. The second category includes drugs that enhance calculi formation through their metabolic effects. The diagnosis of these specific calculi depends on a detailed medical history, associated comorbidities and the patient's history of drug consumption. There are several risk factors associated with drug-induced stones, such as high dose of consumed drugs and long duration of treatment. Moreover, there are some specific risk factors, including urinary pH and the amount of fluid consumed by children. There are limited data regarding pediatric lithogenic drugs, and hence, our aim was to perform a comprehensive review of the literature to summarize these drugs and identify the possible mechanisms involved in calculi formation and discuss the management and preventive measures for these calculi.

show abstract

“…91 In patients with glaucoma, treatments with acetazolamide [92][93][94] and its analogues, methazolamide 95 or dorzolamide 96 are complicated by nephrolithiasis in about 10% of cases. Stones are predominantly made of calcium phosphate.…”

Section: Carbonic Anhydrase Inhibitorsmentioning

confidence: 99%

Drug-Induced Renal Stones

Daudon

Jungers²

2010

Urinary Tract Stone Disease

View full text Add to dashboard Cite

Drug-induced stones represent about 1% of all renal stones. They involve two main mechanisms. The first one includes stones made of the drug and/or its metabolites identified by X-ray diffraction or infrared spectroscopy on the basis of their specific diagrams. Nowadays, the most commonly observed ones are antiproteases (such as indinavir) used in HIV-infected patients, high-dose sulfadiazine used for the treatment of cerebral toxoplasmosis, and abuse of ephedrine/guaifenesin-containing preparations, whereas triamterene, formerly the most often involved drug, is less frequently observed. The second one includes stones of common composition, induced by the metabolic effects of the drug on urinary pH and excretion of calcium, oxalate, phosphate, citrate, uric acid, or other purines. The most frequent causes are unsupervised calcium/vitamin D supplementation and carbonic anhydrase inhibitors, including anticonvulsants (such as topiramate). Incidence of metabolically induced stones is probably underestimated, because they are of apparently usual composition and may reveal long after drug withdrawal. Formation of iatrogenic calculi is favored by high-dose or long-lasting treatments, high renal excretion and low solubility of the drug or its metabolites, low urine output or inadequate urine pH, and is especially frequent in patients with a history of stones. Better awareness of potentially lithogenic drugs may allow more efficient prevention and reduce the incidence of drug-induced nephrolithiasis.

show abstract

Nephrolithiasis With Dorzolamide

Cited by 41 publications

References 2 publications

Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold

Carbonic Anhydrase Inhibitors With Strong Topical Antiglaucoma Properties Incorporating a 4-(2-amino-pyrimidin-4-yl-amino)-benzenesulfonamide Scaffold

Drug-Induced Urolithiasis in Pediatric Patients

Drug-Induced Renal Stones

Contact Info

Product

Resources

About